Hansen Type I Intervertebral Disc Disease

Hansen Type I Intervertebral Disc Disease (IVDD) is a degenerative spinal condition primarily affecting chondrodystrophic dog breeds, characterized by acute, explosive herniation of the nucleus pulposus through a degenerated and mineralized annulus fibrosus into the vertebral canal. This results in spinal cord compression, contusion, and ischemia, leading to varying degrees of neurological dysfunction, from spinal hyperesthesia to complete paraplegia with loss of deep pain perception. The condition is classified as a neurosurgical emergency, and prompt surgical decompression is often required to preserve spinal cord function and prevent irreversible damage.

The primary etiology of Hansen Type I IVDD is premature chondroid metaplasia of the intervertebral disc, a degenerative process that begins early in life in chondrodystrophic breeds. This metaplasia leads to dehydration and mineralization of the nucleus pulposus, reducing its shock-absorbing capacity. The annulus fibrosus becomes weakened and fissured, predisposing to acute rupture. Traumatic events, such as jumping, falling, or vigorous play, can precipitate herniation, but often the extrusion occurs spontaneously during normal activity. Genetic factors play a significant role, with a strong breed predisposition. The condition is not primarily inflammatory or infectious; rather, it is a biomechanical failure of the disc's structural integrity.

Hansen Type I IVDD is most commonly diagnosed in chondrodystrophic breeds, including the Dachshund, Beagle, French Bulldog, Pekingese, Shih Tzu, and Corgi. Dachshunds have the highest incidence, with an estimated lifetime risk of 19-24%. The condition typically presents in young to middle-aged dogs (3-6 years), with no strong sex predilection, although some studies suggest a slight male predominance. Non-chondrodystrophic breeds can also be affected, but they tend to develop Hansen Type II disc disease (progressive protrusion) rather than Type I extrusion. The thoracolumbar region (T11-L2) is the most common site, accounting for approximately 85% of cases, with the cervical region (C2-C7) being the second most common. The lumbosacral region is less frequently involved.

The pathophysiological cascade of Hansen Type I IVDD begins with chondroid metaplasia of the nucleus pulposus, leading to loss of glycosaminoglycans and water content, and subsequent mineralization. This makes the nucleus less resilient and more prone to fragmentation. Concurrently, the annulus fibrosus undergoes degenerative changes, including fissuring and weakening, particularly in its dorsal aspect. When intradiscal pressure exceeds the tensile strength of the annulus, the nucleus pulposus extrudes into the vertebral canal, causing acute spinal cord compression. The extruded disc material triggers a cascade of secondary injury mechanisms: mechanical compression disrupts axonal transport and blood flow, leading to ischemia, edema, and hemorrhage within the spinal cord. Inflammatory mediators, such as cytokines and free radicals, are released, exacerbating neuronal damage. The severity of neurological deficits correlates with the rate and degree of compression, as well as the extent of spinal cord contusion. Chronic compression can lead to demyelination, axonal degeneration, and gliosis, resulting in permanent neurological deficits.

Intrinsic predisposing factors include breed (chondrodystrophic), genetic susceptibility (e.g., a specific mutation in the FGF4 retrogene has been associated with increased risk in Dachshunds), age (young to middle-aged), and obesity, which increases mechanical load on the spine. Extrinsic factors include trauma (jumping, falls, rough play), excessive physical activity, and possibly nutritional factors (high-calorie diets leading to obesity). Prior spinal surgery or concurrent spinal abnormalities may also predispose to disc degeneration. Management of these factors, such as weight control and activity restriction, is crucial in preventing or delaying the onset of clinical signs.

Clinical signs of Hansen Type I IVDD vary depending on the location and severity of spinal cord compression. In thoracolumbar disease, signs range from spinal hyperesthesia (pain on palpation or movement) to ataxia, proprioceptive deficits, paresis, and paralysis. Neurological examination findings are graded using the Modified Frankel Scale: Grade 0 (normal), Grade 1 (spinal hyperesthesia only), Grade 2 (ambulatory paraparesis), Grade 3 (non-ambulatory paraparesis), Grade 4 (paraplegia with intact deep pain perception), and Grade 5 (paraplegia with absent deep pain perception). In cervical disease, signs include neck pain, reluctance to move the head, proprioceptive ataxia in all four limbs, and potentially tetraplegia in severe cases. Horner's syndrome, respiratory compromise, and urinary bladder dysfunction may occur with high cervical lesions. Lumbosacral disease presents with lumbar pain, pelvic limb lameness, and urinary/fecal incontinence.

Differential diagnoses for Hansen Type I IVDD include: (1) Hansen Type II IVDD (progressive protrusion of the annulus fibrosus, more common in non-chondrodystrophic breeds, slower onset); (2) Fibrocartilaginous embolic myelopathy (FCEM) (acute, non-painful, often asymmetric myelopathy due to fibrocartilaginous emboli to the spinal cord); (3) Spinal neoplasia (e.g., meningioma, nerve sheath tumor, osteosarcoma) (progressive, often painful, with vertebral lysis on radiographs); (4) Discospondylitis (infection of the intervertebral disc and adjacent vertebrae, with fever, pain, and radiographic changes); (5) Spinal trauma (fracture/luxation) (history of trauma, vertebral instability on radiographs); (6) Meningomyelitis (inflammatory/infectious, often with systemic signs); (7) Acute non-compressive nucleus pulposus extrusion (ANNPE) (similar to FCEM, but with a history of exercise or trauma, and MRI shows intramedullary changes); (8) Lumbosacral stenosis (cauda equina syndrome) (chronic, progressive, with pain and pelvic limb weakness); (9) Atlantoaxial instability (cervical pain and tetraplegia, often in young small breeds); (10) Syringomyelia (often associated with Chiari-like malformation, with cervical pain and scratching). Definitive diagnosis requires advanced imaging, typically MRI, to differentiate these conditions.

The diagnostic algorithm for suspected Hansen Type I IVDD begins with a thorough history and complete neurological examination, including assessment of proprioception, spinal reflexes, and deep pain perception. If spinal hyperesthesia or neurological deficits are present, thoracic and lumbar radiographs may be obtained to rule out vertebral fractures, luxations, or discospondylitis, but radiographs are not definitive for IVDD. The gold standard for diagnosis is magnetic resonance imaging (MRI), which provides detailed visualization of the spinal cord, intervertebral discs, and extruded disc material. MRI is superior to computed tomography (CT) and myelography for assessing spinal cord compression and parenchymal changes. If MRI is unavailable, CT myelography can be used, but it is invasive and carries risks. In cases where surgery is planned, advanced imaging is essential for surgical planning, including localization of the herniated disc and assessment of the extent of compression. Electrodiagnostic testing (e.g., electromyography, motor evoked potentials) may be used to assess spinal cord function but is not routinely performed.

Laboratory findings in Hansen Type I IVDD are typically unremarkable, as the condition is not associated with systemic inflammatory or metabolic abnormalities. Complete blood count (CBC) and serum biochemistry profile are usually within normal limits, although stress leukogram may be present due to pain. Urinalysis may reveal evidence of urinary tract infection if bladder dysfunction is present. Coagulation profile (PT/aPTT) is recommended prior to surgery to assess bleeding risk. Cerebrospinal fluid (CSF) analysis may be performed if inflammatory or infectious disease is suspected; in IVDD, CSF may show mild albuminocytologic dissociation (elevated protein with normal cell count) due to spinal cord compression. Synovial fluid analysis is not relevant. Inflammatory biomarkers such as C-reactive protein (CRP) may be mildly elevated but are not specific.

Radiography: Survey spinal radiographs may show narrowing of the intervertebral disc space, mineralization of the disc (in chondrodystrophic breeds), and sometimes a small amount of disc material in the vertebral canal, but these findings are not sensitive or specific. Myelography (injection of contrast into the subarachnoid space) can demonstrate extradural compression but is invasive and has been largely replaced by advanced imaging. Computed Tomography (CT): CT is excellent for detecting mineralized disc material and can be used for surgical planning, especially for cervical and thoracolumbar disc extrusions. CT myelography combines CT with intrathecal contrast to identify compressive lesions. Magnetic Resonance Imaging (MRI): MRI is the imaging modality of choice, providing high-resolution images of the spinal cord, disc degeneration (decreased signal on T2-weighted images), and extruded disc material (often hyperintense on T2, hypointense on T1). MRI also reveals spinal cord edema, hemorrhage, and syringomyelia. MRI is essential for accurate diagnosis and surgical planning, and it can differentiate IVDD from other myelopathies.

Cytology and histopathology are not typically performed for diagnosis of Hansen Type I IVDD, as the condition is diagnosed based on imaging and clinical signs. However, if surgery is performed, the extruded disc material may be submitted for histopathology to confirm the diagnosis and rule out neoplasia. Histologically, the nucleus pulposus shows chondroid metaplasia with loss of notochordal cells, decreased proteoglycan content, and mineralization. The annulus fibrosus exhibits fissures and tears. In chronic cases, there may be fibrocartilaginous proliferation and neovascularization. If a mass is suspected, fine-needle aspiration or biopsy may be performed, but this is not routine.

Treatment of Hansen Type I IVDD can be medical or surgical, depending on the severity of neurological signs. Medical management is reserved for dogs with mild signs (Grade 1 or ambulatory Grade 2) and consists of strict cage rest (4-6 weeks), anti-inflammatory doses of corticosteroids (e.g., prednisone 0.5-1.0 mg/kg PO q12h, tapering) or NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h), and analgesic medications (e.g., gabapentin 10-20 mg/kg PO q8-12h). Muscle relaxants such as methocarbamol (15-20 mg/kg PO q8h) may be used for muscle spasms. Surgical decompression is indicated for dogs with non-ambulatory paresis (Grade 3), paraplegia (Grade 4), or progressive neurological deterioration, and for those with severe pain unresponsive to medical therapy. The goal of surgery is to remove the extruded disc material and decompress the spinal cord. Surgical techniques include: (1) Hemilaminectomy for thoracolumbar disc extrusions, which involves removal of the vertebral lamina and pedicle on the affected side to access the vertebral canal; (2) Dorsal laminectomy for cervical disc extrusions, which removes the dorsal lamina to expose the spinal cord; (3) Ventral slot for cervical disc extrusions, which involves drilling a slot in the ventral aspect of the vertebral bodies to access the disc space and remove the herniated material. In some cases, fenestration of the affected disc and adjacent discs may be performed to prevent future herniation, but this is controversial. Postoperative care includes pain management (opioids, NSAIDs, local anesthetics), bladder management (manual expression or catheterization), and physical rehabilitation (passive range of motion, massage, swimming, walking). The prognosis for recovery depends on the severity of neurological deficits and the timing of surgery. Dogs with intact deep pain perception have a good to excellent prognosis (80-95% recovery), while those with absent deep pain perception have a guarded prognosis (50-60% recovery).

The prognosis for Hansen Type I IVDD is highly dependent on the neurological grade at presentation and the speed of intervention. For dogs with ambulatory paresis (Grade 2), the prognosis is excellent with medical or surgical management, with over 90% recovering. For non-ambulatory paraparesis (Grade 3), surgical decompression yields a good prognosis, with 80-90% regaining ambulation. Paraplegic dogs with intact deep pain perception (Grade 4) have a good prognosis (80-95%) if surgery is performed within 24-48 hours of onset. Paraplegic dogs with absent deep pain perception (Grade 5) have a guarded prognosis, with only 50-60% recovering ambulation, and a significant risk of permanent paralysis and urinary incontinence. Negative prognostic indicators include loss of deep pain perception for more than 48 hours, severe spinal cord hemorrhage or myelomalacia on MRI, and progressive neurological deterioration despite treatment. Complications of surgery include wound infection, seroma formation, hemorrhage, and recurrence of disc herniation (5-10% risk). Long-term outcome is generally favorable, with most dogs regaining normal urinary and fecal continence and ambulation, although some may have residual proprioceptive deficits.

Postoperative follow-up for Hansen Type I IVDD includes: (1) Immediate postoperative period: monitor neurological status, pain, and urinary bladder function. Administer analgesics and antibiotics as prescribed. (2) 2 weeks: suture removal, recheck neurological examination, and initiate physical rehabilitation. (3) 4-6 weeks: recheck radiographs or MRI if needed to assess surgical site and spinal cord status. Gradually increase activity as neurological function improves. (4) 8-12 weeks: full recheck, including neurological examination and assessment of ambulation. Most dogs have achieved maximal improvement by this time. (5) Long-term: annual rechecks to monitor for recurrence or development of other disc herniations. Owners should be advised on weight management, activity restriction (no jumping or rough play), and use of a harness instead of a collar to reduce cervical strain. Physical therapy, including hydrotherapy and therapeutic exercises, is beneficial for muscle strength and coordination.

Clinical Pearls: (1) In thoracolumbar IVDD, the most common site is T12-L1, so surgical approach should be centered on the affected disc space. (2) Preoperative MRI is essential to accurately localize the herniation and plan the surgical approach. (3) In cervical IVDD, ventral slot is preferred for C2-C7 disc extrusions, but care must be taken to avoid damage to the vertebral arteries and spinal cord. (4) Use of a high-speed burr and magnification (loupes or microscope) improves surgical precision. (5) Postoperative physical rehabilitation is crucial for optimal recovery. Pitfalls: (1) Delaying surgery in non-ambulatory dogs can lead to irreversible spinal cord damage. (2) Incomplete removal of disc material can result in persistent compression and poor recovery. (3) Excessive hemorrhage during surgery can obscure the surgical field and increase morbidity. (4) Failure to recognize and manage urinary bladder dysfunction can lead to urinary tract infections and detrusor atony. (5) Overuse of corticosteroids in the perioperative period can impair wound healing and increase infection risk.

Perioperative drug protocols for Hansen Type I IVDD surgery: (1) Prophylactic antimicrobials: Cefazolin 22 mg/kg IV at induction and every 90 minutes during surgery, then every 8 hours for 24 hours postoperatively. (2) Analgesics: Preoperative: Methadone 0.2-0.5 mg/kg IV or IM, or hydromorphone 0.05-0.1 mg/kg IV. Intraoperative: Fentanyl CRI at 5-10 mcg/kg/hr. Postoperative: Morphine 0.5-1.0 mg/kg IM or IV q4-6h, or buprenorphine 0.01-0.02 mg/kg IV q6-8h. Transition to oral tramadol 2-5 mg/kg PO q8-12h and gabapentin 10-20 mg/kg PO q8-12h. (3) NSAIDs: Carprofen 2.2 mg/kg PO q12h or meloxicam 0.1 mg/kg PO q24h, starting 24 hours after surgery if no contraindications. (4) Muscle relaxants: Methocarbamol 15-20 mg/kg PO q8h for muscle spasms. (5) Corticosteroids: Dexamethasone 0.1-0.2 mg/kg IV once intraoperatively, or prednisone 0.5-1.0 mg/kg PO q12h tapering over 7-10 days, but use with caution due to potential side effects. (6) Gastroprotectants: Omeprazole 1 mg/kg PO q12h or famotidine 0.5 mg/kg PO q12h to prevent gastric ulcers, especially if corticosteroids are used. (7) Bladder management: If urinary retention, consider bethanechol 2.5-10 mg PO q8h to stimulate bladder contraction, and antibiotics if urinary tract infection is present.

Landmark studies and consensus guidelines: (1) A seminal study by Hansen (1952) first classified intervertebral disc disease into Type I and Type II based on histopathology. (2) A prospective study by Olby et al. (2003) evaluated the use of decompressive surgery in dogs with thoracolumbar IVDD and found that dogs with intact deep pain perception had a 95% recovery rate, while those without had a 50% recovery rate. (3) A randomized controlled trial by Jeffery et al. (2016) compared surgical versus medical management for dogs with non-ambulatory paraparesis and found that surgery resulted in faster recovery and better long-term outcomes. (4) A meta-analysis by Moore et al. (2016) confirmed that surgical decompression is superior to medical management for dogs with severe neurological deficits. (5) The ACVS consensus statement on IVDD recommends early surgical intervention for non-ambulatory dogs and emphasizes the importance of MRI for accurate diagnosis and surgical planning. (6) A study by Flegel et al. (2011) demonstrated that the use of a high-speed burr and microsurgical techniques reduces surgical complications and improves outcomes. (7) Recent research has focused on the role of neuroprotective agents, such as polyethylene glycol and minocycline, but these are not yet standard of care. Overall, the evidence strongly supports surgical decompression for Hansen Type I IVDD in dogs with significant neurological deficits, with a favorable prognosis if deep pain perception is intact.